Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.0%
0%
-16.0%
6 Months
-22.22%
0%
-22.22%
1 Year
-61.11%
0%
-61.11%
2 Years
-87.65%
0%
-87.65%
3 Years
-96.72%
0%
-96.72%
4 Years
-96.32%
0%
-96.32%
5 Years
-97.52%
0%
-97.52%
TheraCryf Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
6.58%
EBIT to Interest (avg)
-3.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.69
Sales to Capital Employed (avg)
0.15
Tax Ratio
6.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.79
EV to EBIT
-0.27
EV to EBITDA
-0.28
EV to Capital Employed
0.31
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-114.56%
ROE (Latest)
-32.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Mar'23
Mar'23
Mar'22
Change(%)
Net Sales
0.40
0.00
Operating Profit (PBDIT) excl Other Income
-5.10
-3.20
-59.38%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.00
-2.70
-48.15%
Operating Profit Margin (Excl OI)
-11,470.60%
0.00%
-1,147.06%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2023 is 0.00% vs -100.00% in Mar 2022
Consolidated Net Profit
YoY Growth in year ended Mar 2023 is -48.15% vs 0.00% in Mar 2022
About TheraCryf Plc 
TheraCryf Plc
Pharmaceuticals & Biotechnology
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.
Company Coordinates 
Company Details
The Colony, 146 Brownlow Hill, Altrincham Road WILMSLOW None : SK9 4LY
Registrar Details






